ArticleBMC anesthesiology2025
Analysis of perioperative period coagulation function affected by anti-seizure medications in epilepsy surgery.
Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-resistant epilepsy is a chronic condition that refers to epilepsy that does not improve with adequate medication treatment. For such cases, surgical intervention is a crucial strategy. However, in some patients, hemorrhage may occur after the operation. Proper management of anti-seizure medications is essential for perioperative care in epilepsy surgery. It should be noted that certain anti-seizure medications may negatively affect coagulation function. In this study, we aim to summarize the coagulation function of epilepsy patients during the perioperative period and compare the postoperative coagulation function when using sodium valproate and levetiracetam.
methodEighty-two epilepsy patients (age = 30.79 ± 10.30 years old; M:F = 49:33) who underwent surgical treatments in Peking Union Medical College Hospital from April 2019 to April 2023 were enrolled in the study. Coagulation functions were evaluated using laboratory examination. Based on their perioperative medication, they were divided into two groups - sodium valproate and levetiracetam. We used t-test to measure the coagulation function parameters affected by the operation and then used independent t-test to determine the differences in coagulation function between the two groups.
resultAbnormal PT, APTT, Fbg within 3 days after operation were found 84.8%, 28.3%, 93.5% respectively in patients using sodium valproate intravenous preparation, while these parameters were 38.9%, 25.0%, 83.3% respectively in patients using levetiracetam intravenous preparation. The patients who took sodium valproate intravenous preparation get higher value of PT increase in perioperative time compared to patients using levetiracetam intravenous preparation.
conclusionPatients with epilepsy are at risk of experiencing abnormal coagulation function following epilepsy surgery. It has been observed that patients may experience more severe and prolonged prothrombin time (PT) when using intravenous valproic acid preparation during the perioperative period, as compared to using levetiracetam intravenous preparation. These findings highlight the importance of monitoring coagulation function after epilepsy surgery. Surgeons should closely monitor patients who receive sodium valproate treatment during the perioperative period for any potential impact on their coagulation function post-surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.